1	Original Article
2	Dynamics of cellular immune responses in the acute phase of dengue virus
3	infection
4	
5	
6	Tomoyuki Yoshida, Tsutomu Omatsu, Akatsuki Saito, Yuko Katakai, Yuki
7	Iwasaki, Terue Kurosawa, Masataka Hamano, Atsunori Higashino, Shinichiro
8	Nakamura, Tomohiko Takasaki, Yasuhiro Yasutomi, Ichiro Kurane and Hirofumi
9	Akari
10	
11	T. Yoshida · Y. Iwasaki · T. Kurosawa · M. Hamano · Y. Yasutomi · H. Akari
12	Tsukuba Primate Research Center, National Institute of Biomedical Innovation, 1-1
13	Hachimandai, Tsukuba, Ibaraki 305-0843, Japan
14	
15	T. Yoshida (E-mail)· A. Saito · A. Higashino · H. Akari (E-mail)
16	Center for Human Evolution Modeling Research, Primate Research Institute, Kyoto
17	University, Inuyama, Aichi 484-8506, Japan
18	E-mail: yoshida.tomoyuki.4w@kyoto-u.ac.jp
19	H. Akari
20	E-mail: akari.hirofumi.5z@kyoto-u.ac.jp
21	
22	T. Omatsu · T. Takasaki · I. Kurane
23	Department of Virology I, National Institute of Infectious diseases, 1-23-1 Toyama,
24	Shinjuku-ku, Tokyo 162-8640, Japan
25	
26	A. Saito
27	International Research Center for Infectious Diseases, The Institute of Medical Science,
28	The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
29	
30	Y. Katakai · M. Hamano
31	Corporation for Production and Research of Laboratory Primates, 1-1 Hachimandai,

Corporation for Production and Research of Laboratory Primates, 1-1 Hachimandai,

32 Tsukuba, Ibaraki 305-0843, Japan

33

- 34 S. Nakamura
- 35 Research Center for Animal Life Science, Shiga University of Medical Science, Seta
- 36 Tsukinowa-cho, Otsu, Shiga 520-2192, Japan
- 37
- 38 *Address corresponding: T. Yoshida, Primate Research Institute, Kyoto University,
- 39 Inuyama, Aichi 484-8506, Japan.
- 40 E-mail: yoshida.tomoyuki.4w@kyoto-u.ac.jp
- 41
- 42 *Address corresponding: H. Akari, Primate Research Institute, Kyoto University,
- 43 Inuyama, Aichi 484-8506, Japan.
- 44 E-mail: akari.hirofumi.5z@kyoto-u.ac.jp

45

- 46 T. Yoshida and T. Omatsu contributed equally to this study.
- 47 Key words: Dengue virus, marmoset, CD4, CD8.

48

48 Abstract

49In this study we sought to examine the dynamics of cellular immune responses in the 50acute phase of dengue virus (DENV) infection in a marmoset model. Here we found that the DENV infection in marmosets greatly induced responses of CD4/CD8 central 5152memory T and NKT cells. Interestingly, the strength of the immune responses were 53greater in the animals infected with a dengue fever strain than those with a dengue 54hemorrhagic fever strain of DENV. In contrast, at the re-challenge of the same DENV 55strain as a primary infection, a neutralizing antibody induced likely played a critical role 56in sterilizing inhibition against the viral replication, resulting in strong but delayed responses of CD4/CD8 central memory T and NKT cells. Our results in this study may 57help better understand the dynamics of cellular and humoral immune responses in the 5859control of DENV infection.

60 Introduction

61

62 DENV causes the most prevalent arthropod-borne viral infections in the world [29]. 63 Infection with one of the four serotypes of DENV will lead to dengue fever (DF) and 64 sometimes the fatal dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS) 65 [12]. The serious diseases likely develop more frequently following secondary infection 66 with a serotype of DENV different from that of the primary infection. Infection with 67 DENV induces a high-titered neutralizing antibody that can provide long-term 68 immunity to the homologous DENV serotype while the effect of the antibody on the 69 heterologous serotypes is transient [22]. On the other hand, enhanced pathogenicity 70after secondary DENV infection appears to be explained by antibody dependent 71enhancement (ADE): mouse and monkey experiments have shown that sub-neutralizing 72levels of DENV-specific antibodies actually enhance infection [1, 6, 11]. Thus, development of an effective tetravalent dengue vaccine is considered to be of public 7374health priority. There are recently several vaccine candidates for DENV infection under 75clinical trials, and most of them target the induction of neutralizing antibodies [20].

76Research of the long-term immune response in humans has provided several 77interesting parallels to the data. It was reported that complete cross-protective immunity 78from heterologous challenge was induced in individuals 1-2 months after a primary 79DENV infection, with partial immunity present up to 9 months resulting in a milder 80 disease of shorter duration on reinfection, and that complete serotype-specific immunity 81 against symptomatic dengue was observed up to 18 months post-infection [30]. Guzman 82 and Sierra have previously recorded the long-term presence of both DENV-specific 83 antibodies and T cells up to 20 years after natural infections [10, 31]. Of note, increased 84 T cell activation is reportedly associated with severe dengue disease [7, 8]. Thus, the 85 balance between humoral and cellular immunity may be important in the control of 86 dengue diseases.

87 However, the detail regarding the implication of humoral and cellular immunity 88 in controlling DENV infection remains to be elucidated. Previously, passive transfer of 89 either monoclonal or polyclonal antibodies was shown to protect against homologous 90 DENV challenge [13, 15, 16]. It was also reported that neutralizing antibodies played a 91 greater role than cytotoxic T lymphocytes (CTL) responses in heterologous protection 92 against secondary DENV infection *in vivo* in IFN- $\alpha/\beta R^{-/-}$ and IFN $\gamma R^{-/-}$ mouse models

[18]. Moreover, CD4⁺ T cell depletion did not affect the DENV-specific IgG or IgM Ab 93 titers or their neutralizing activity in the IFN $\gamma R^{-/-}$ mouse model [36]. On the other hand, 94 95 there are several reports showing that cellular immunity rather than humoral immunity 96 plays an important role in the clearance of DENV. For example, in adoptive transfer 97 experiments, although cross-reactive DENV-1-specific CD8⁺ T cells did not mediate protection against a DENV-2 lethal infection, adoptive transfer of CD4⁺ T cells alone 98 mediated protection and delayed mortality in IFN- $\alpha/\beta R^{-/-}$ and IFN $\gamma R^{-/-}$ mouse models 99 [39]. It has also been demonstrated that $CD8^+$ T lymphocytes have a direct role in 100 protecting DENV challenge in the IFN- $\alpha/\beta R^{-/-}$ mouse model of DENV infection by 101 102 depleting CD8⁺ T cells [35]. In addition, previous data from adoptive-transfer 103 experiments in BALB/c mice showed that cross-reactive memory CD8⁺ T cells were 104 preferentially activated by the secondary DENV infection, resulting in augmented IFN-y 105 and tumor necrosis factor- α (TNF- α) responses, and that this effect was 106 serotype-dependent [2, 3]. Although it has previously been suggested that inducing neutralizing antibodies against DENV may play an important role in controlling DENV 107 108infection, CTL are also proposed to contribute to clearance during primary DENV 109 infection and in pathogenesis during secondary heterologous infection in the BALB/c 110 mouse model [4].

111 Why did the mouse models in DENV infection show inconsistent results *in* 112 *vivo*? One of the reasons could be that these results were obtained mainly from 113 genetically manipulated mice such as the IFN- $\alpha/\beta R^{-/-}$ and IFN $\gamma R^{-/-}$ mice. Moreover, 114 these mice were inoculated with 10^9 - 10^{10} genome equivalents (GE) of DENV [27, 35, 115 36], which were likely large excess as compared with humans injected with 10^4 - 10^5 GE 116 of DENV by a mosquito [19]. In addition, efficiency of DENV replication in wild mice 117 *in vivo* was very low compared with humans [35].

Recently, novel non-human primate models of DENV infection using rhesus 118 119 macaques as well as marmosets and tamarins have been developed [24-26, 38]. An 120intravenous challenge of rhesus macaques with a high dose of virus inoculum (1×10^7) 121GE) of DENV-2 resulted in readily visible hemorrhaging, which is one of the cardinal 122symptoms of human DHF [26]. It was also shown that the cellular immune response was activated due to expression of IFN- γ , TNF- α , and macrophage inflammatory 123protein-1 β in CD4⁺ and CD8⁺ T cells during primary DENV infection in rhesus 124125macagues [20]. On the other hand, in the marmoset model of DENV infection, we

 $\mathbf{5}$

observed high levels of viremia $(10^5-10^7 \text{ GE/ml})$ after subcutaneous inoculation with 12612710⁴-10⁵ plaque forming unit (PFU) of DENV-2. Moreover, we demonstrated that 128DENV-specific IgM and IgG were consistently detected, and that the DENV-2 genome 129was not detected in any of these marmosets inoculated with the same DENV-2 strain as 130 the primary infection [24]. It is notable that while neutralizing antibody titers were at 131levels of 1:20-1:80 before the re-challenge inoculation, the titers increased up to 1321:160-1:640 after the re-challenge inoculation [24]. These results suggested that the 133 secondary infection with DENV-2 induced a protective humoral immunity to DENV-2, 134 and that DENV-infected marmoset models may be useful in order to analyze the 135relationship between DENV replication and dynamics of adaptive immune responses in 136 vivo.

Taking these findings into consideration, we sought to investigate the dynamics
of cellular immunity in response toward primary and secondary DENV infection in the
marmoset model.

140

140 Materials and methods

141

142 Animals

143 All animal studies were conducted in accordance with the protocols of experimental 144procedures that were approved by the Animal Welfare and Animal Care Committee of 145the National Institute of Infectious Diseases, Japan, and the National Institute of 146 Biomedical Innovation, Japan. A total of 6 male marmosets, weighing 258-512 g, were 147used. Common marmosets were purchased from Clea Japan Inc. (Tokyo, Japan), and 148 caged singly at 27±2 °C in 50±10% humidity with a 12h light-dark cycle (lighting from 1497:00 to 19:00) at Tsukuba Primate Research Center, National Institute of Biomedical 150Innovation, Tsukuba, Japan. Animals were fed twice a day with a standard marmoset 151diet (CMS-1M, CLEA Japan) supplemented with fruit, eggs and milk. Water was given 152ad libitum. The animals were in a healthy condition and confirmed to be negative for 153anti-dengue virus antibodies before inoculation with dengue virus [24].

154

155 Cells

Cell culture was performed as previously described [24]. Vero cells were cultured in
Minimum Essential Medium (MEM, Sigma) with 10% heat-inactivated fetal bovine
serum (FBS, GIBCO) and 1% non-essential amino acid (NEAA, Sigma) at 37 °C in 5 %
CO₂. C6/36 cells were cultured in MEM with 10% FBS and 1% NEAA at 28 °C in 5 %
CO₂.

161

162 Virus

DENV type 2 (DENV-2), DHF0663 strain (Accession no. AB189122) and 163 164 D2/Hu/Maldives/77/2008NIID (Mal/77/08) strain were used for inoculation studies. 165The DENV-2, DHF0663 strain was isolated from a DHF case in Indonesia. The 166 DENV-2, Mal/77/08 strain was isolated from imported DF cases from Maldives. All 167 DENV strains isolated clinical samples were propagated with C6/36 cells and were used 168 within 4 passages on C6/36 cells. Culture supernatant from infected C6/36 cells was 169 centrifuged at 3,000 rpm for 5 min to remove cell debris, and then stored at -80 °C until 170 use.

171

172 Infection of the marmosets with DENV

173In the challenge experiments, the profiling of the key adaptive and innate immune cells 174in the marmosets after infection with serotype 2 of DENV (DENV-2) was examined. At the primary DENV infection, four marmosets were inoculated subcutaneously in the 175back with either 1.9 $\times 10^5$ PFU of the DENV-2 Mal/77/08 strain (Cj08-007, Cj07-011) 176or 1.8x10⁴ PFU of the DHF0663 strain (Cj07-006, Cj07-008) [24]. In the case of the 177DENV re-challenge experiment, two marmosets initially inoculated with 1.8x10⁵ PFU 178179of the DHF0663 strain were re-inoculated 33 weeks after the primary challenge with 1.8x10⁵ PFU of the same strain (Cj07-007, Cj07-014) [24]. Blood samples were 180 collected on days 0, 1, 3, 7, 14, and 21 after inoculation and were used for virus titration 181 and flow cytometric analysis. Inoculation with DENV and blood drawing was 182183 performed under anesthesia with 5 mg/kg of ketamine hydrochloride. Day 0 was 184 defined as the day of virus inoculation. The viral loads in marmosets obtained in a 185previous study were shown in Supplementary Figure 1 [24].

186

187 Flow cytometry

188Flow cytometry was performed as previously described [37]. Fifty microliters of whole 189 blood from marmosets was stained with combinations of fluorescence-conjugated 190 monoclonal antibodies; anti-CD3 (SP34-2; Becton Dickinson), anti-CD4 (L200; BD 191 Pharmingen), anti-CD8 (CLB-T8/4H8; Sanquin), anti-CD16 (3G8; BD Pharmingen), 192 anti-CD95 (DX2; BD Pharmingen), and anti-CD62L (145/15; Miltenyi Biotec). Then, erythrocytes were lysed with FACS lysing solution (Becton Dickinson). After washing 193 194 with a sample buffer containing phosphate-buffered saline (PBS) and 1% fetal calf 195serum (FCS), the labeled cells were resuspended in a fix buffer containing PBS and 1% 196 formaldehyde. The expression of these markers on the lymphocytes was analyzed with 197 FACSCanto II flow cytometer (Becton Dickinson). The data analysis was conducted 198 using a FlowJo software (Treestar, Inc.). Results were shown as mean±standard 199 deviation (SD) from the marmosets used in this study. 200

- 200 Results
- 201

202 Naïve, central/effector memory T cells and NK/NKT cells in marmosets

203Basic information regarding CD4/CD8 naïve and central/effector memory T cells and 204 NK/NKT cells in common marmosets was unavailable. Thus, we examined the 205immunophenotypes of lymphocyte subsets in the marmosets (Fig. 1). The gating 206 strategy for profiling the CD4 and CD8 T cells in the marmosets by FACS is shown in 207Figure 1a. Human T cells are classically divided into 3 functional subsets based on their 208cell surface expression of CD62L and CD95, i.e. $CD62L^+CD95^-$ naive T cells (T_N), CD62L⁺CD95⁺ central memory T cells (T_{CM}), and CD62L⁻CD95[±] effector memory T 209cells (T_{EM}) [9, 21, 28]. In this study, CD4⁺ and CD8⁺ T_N , T_{CM} , and T_{EM} subpopulations 210were defined as CD62L⁺CD95⁻, CD62L⁺CD95⁺, and CD62L⁻CD95[±], respectively (Fig. 2112121a and Table 1). The average ratio of CD3⁺ T lymphocytes in the total lymphocytes of 3 213marmosets was found to be $75.7\pm6.4\%$. The average ratio of CD4⁺ T cells in the CD3⁺ subset was 65.4±6.8%. The average ratios of CD4⁺ T_N , T_{CM} , and T_{EM} cells were 214 21565.9±3.7%, 16.4±2.9%, 19.5±2.5%, respectively. The average ratio of CD8⁺ T cells in the CD3⁺ subset was 29.0 \pm 8.0%. The average ratios of CD8⁺ T_N, T_{CM}, and T_{EM} cells 216217were 66.7±10.2%, 4.7±3.6%, 28.8±14.8%, respectively.

218We recently characterized a CD16⁺ major NK cell subset in tamarins and 219compared NK activity in tamarins with or without DENV infection [37, 38]. In terms of 220NKT cells, NK1.1 (CD161) and CD1d are generally used as markers of NKT cells [32]. 221However, so far these anti-human NK1.1 and CD1d antibodies are unlikely to 222cross-react with the NKT cells of the marmosets. Thus, we defined NKT cells as a 223population expressing both CD3 and CD16 as previously reported [14, 17]. The NK and 224NKT cell subsets were determined to be CD3⁻CD16⁺ and CD3⁺CD16⁺ lymphocytes in 225the marmosets. The average ratios of NK and NKT cell subsets in the lymphocytes were 226 4.2±2.6% and 5.1±3.4%, respectively (Table 1). We observed that the proportions of the 227major lymphocyte subsets in the marmosets were similar to those in cynomolgus 228monkeys and tamarins [37, 38].

229

230 **Profiling of CD4 and CD8 T, NK and NKT cells in the marmosets infected with**

- 231 primary DENV-2 (Mal/77/08 strain)
- 232 We investigated the cellular immune responses against DENV-2 DF strain (Mal/77/08)

233in marmosets. Dengue vRNA was detected in plasma samples from two marmosets on 234day 2 post-infection (Supplementary Fig. 1a). For each of the two marmosets (Cj08-007, Ci07-011), the plasma levels of vRNA reached their peaks at 9.6×10^6 and 7.0×10^6 235236GE/ml on day 4 post-infection, respectively. The plasma vRNA was detected in both 237marmosets on days 2, 4, and 7. We then examined the profiling and frequencies of the 238CD4 and CD8 T, NK and NKT cells in the infected marmosets (Figs. 2-3 and Table 2). CD4^+ T_{CM} cells drastically increased to 88.7±2.8% from 13±0.4% between day 0 and 239day 2 post-inoculation (Table 2). Reciprocally, CD4⁺ T_N cells completely decreased to 240 $1.6\pm3.3\%$ from 74.1±0.9% at the same time. CD4⁺ T_{EM} cells maintained the initial 241242levels throughout the observation periods. $CD8^+ T_{CM}$ cells increased to 91.9±5.5% from 2.1±0.8% between day 0 day 2 post-inoculation, and reciprocally $CD8^+$ T_N cells 243decreased to 2.5±4.7% from 89.9±2.5% at the same time. In addition, NK cells 244245maintained their initial levels throughout the observation periods. However, NKT cells 246drastically increased to 52.6±17% from 0.2±0.0% between day 0 and day 2 247post-inoculation. These results suggest that CD4/CD8 T and NKT cells may efficiently 248respond to the Mal/77/08 strain of DENV.

249

Profiling of CD4 and CD8 T, NK and NKT cells in the marmosets infected with primary DENV-2 (DHF0663 strain)

252Next, we investigated the cellular immune responses against another DENV-2 DHF 253strain (DHF0663) in marmosets. Dengue vRNA was detected in plasma samples from 254the marmosets on day 2 post-infection ([24], Supplementary Fig. 1b). For each of the two marmosets (Cj07-006, Cj07-008), the plasma vRNA levels were shown to be 255 3.4×10^5 and 3.8×10^5 GE/ml on day 2 and 2.0×10^6 and 9.4×10^5 GE/ml at the peak on day 2562574 post-infection, respectively, followed by being undetectable on day 14. Thus, we 258examined the profiling and frequencies of the CD4⁺ and CD8⁺ T, NK and NKT cells in 259these DENV-infected marmosets (Fig. 4-5 and Table 3). It was found that on day 7 260post-inoculation CD4⁺ and CD8⁺ T_N cells decreased and in contrast the T_{CM} populations 261increased in both marmosets, however, the changes in proportion were much less than 262the case of the marmosets infected with the DF strain. We observed no consistent 263tendency in the kinetics of CD4⁺ and CD8⁺ T_{EM} cells nor in NK and NKT cells. These 264results suggest that the strength of T cell responses may be dependent on the strain of 265DENV.

266

Profiling of CD4 and CD8 T, NK and NKT cells in the marmosets re-challenged with a DENV-2 strain

269In order to examine the cellular immune responses against the re-challenge of DENV-2 270DHF strain in marmoset model, marmosets were infected twice with the same DENV-2 271strain (DHF0663) at 33 weeks interval after the primary infection. The results showed 272that vRNA and NS1 antigens were not detected in plasma and that the neutralizing 273antibody titer was obviously increased after the secondary infection. The data indicated 274that the primary infection induced protective immunity including a neutralizing 275antibody to the re-challenge of the same DENV strain ([24]; Supplementary Fig.1c). We also investigated the profiling of the CD4 and CD8 T, NK and NKT cells in the 276277marmosets (Cj07-007, Cj07-014) re-challenged with the same DENV-2 strain (DHF0663) (Fig. 6-7). CD4⁺ T_{CM} cells drastically increased on day 14 post-inoculation. 278On the other hand, $CD4^+$ T_N cells completely decreased at the same time. $CD4^+$ T_{EM} 279cells maintained their initial levels through the observation periods. Similarly $CD8^+ T_{CM}$ 280281and NKT cells clearly increased on day 14 post-inoculation. Importantly, these T cell 282responses were induced one week after the obvious induction of the neutralizing 283antibody in the marmosets [24]. These results suggest that the neutralizing antibody 284may play a critical role in the complete inhibition of the secondary DENV infection. 285

285 **Discussion**

286

287In this study, we demonstrated the dynamics of the central/effector memory T cells and 288NK/NKT subsets against DENV infection in our marmoset model. First, we 289characterized the central/effector memory T and NK/NKT subsets in marmosets (Fig. 1). 290 Second, we found that CD4/CD8 central memory T cells and NKT cells had significant 291responses in the primary DENV infection and the levels were likely to be dependent on 292 the strain of the virus employed for challenge experiments (Fig. 2-5). Finally, we found 293delayed responses of CD4/CD8 central memory T cells in the monkeys re-challenged 294with the same DENV DHF strain, irrespective of the complete inhibition of the DENV 295replication. (Fig. 6-7).

296The present study shed light on the dynamics of cellular and humoral immune 297 responses against DENV in vivo in the marmoset model. Our results showed that 298cellular immune responses were induced earlier than that of antibody responses in the 299primary infection. Thus, our results suggest the possibility that cellular immunity may 300 contribute, at least in part, to the control of primary DENV infection. On the other hand, 301 in the presence of neutralizing antibodies in the re-challenged monkeys [24], delayed 302 (on day14 after the re-challenge) responses of CD4/CD8 central memory T cells were 303 observed irrespective of the complete inhibition of the DENV replication. These results 304 indicate that the cellular immunity is unlikely to play a major role in the control of the 305 DENV re-infection. Alternatively, it is still possible that cellular immunity, such as memory T cells, could partially play a helper role for the enhanced induction of 306 307 neutralizing antibodies even without an apparent increase in the proportion of T_{CM} , 308 resulting in efficient prevention of DENV replication.

309 It is possible that the DENV strains used in this study may influence the strength 310 of cellular immune responses. The differences in cellular immune responses between 311 the monkeys infected with the DF or DHF strain may not be caused by individual 312 differences in marmosets because the FACS results were consistent with each 2 313 marmosets. It was previously shown that there was a reduction in CD3, CD4, and CD8 314 cells in DHF and demonstrated that lower levels of CD3, CD4, and CD8 cells 315 discriminated DHF from DF patients during the febrile stage of illness [5]. There was a 316 significant increase in an early activation marker on CD8⁺ T cells in children with DHF 317 compared with DF during the febrile period of illness [8]. Another group reported that

levels of peripheral blood mononuclear cell apoptosis were higher in children 318 319 developing DHF [23]. Moreover, cDNA array and ELISA screening demonstrated that 320 the IFN-inducible genes, IFN-induced genes and IFN production were strongly 321up-regulated in the DF patients compared with the DHF patients, suggesting a 322 significant role of IFN system during DF strain infection compared with DHF strain 323 infection [34]. Thus, it is reasonable to assume that the DHF strain might have an ability 324 to negatively regulate T cell responses. A recent report demonstrating that the sequence 325 of the DHF strain differed from that of DF strain in six unique amino acid residues 326 located in the membrane, envelope and non-structural genes [33], which supports our 327 notion.

328 Alternatively, the other possibility is that the strength of T cell responses might 329 depend on the viral loads. In fact, in our results the greater T cell responses in the DF 330 strain-infected monkeys were paralleled with higher viral loads, which was in contrast 331 with the result of the DHF strain-infected animals with lower viral loads. Of note, the ten-fold more challenge dose of the DF strain used in this study (1.9 $\times 10^5$ PFU) than 332 that of the DHF strain $(1.8 \times 10^4 \text{ PFU})$ could have simply led to ten-fold more peak viral 333 334 RNA levels in the DF strain-infected monkeys. In either case, the relationship between 335 the strength of antiviral immune responses and the viral strains remains to be elucidated. 336 Further in vivo characterization of the antiviral immunity and the viral replication 337 kinetics induced by infection of various DENV strains isolated from DF and DHF 338 patients will help understand the mechanism of differential disease progression in the 339 course of DENV infection.

340 We observed that dengue vRNA was not detected in plasma samples from 341 marmosets re-infected with the same DENV-2 DHF strain at 33 weeks as the primary 342 infection. This result suggests that memory B cells induced in the primary DENV 343 infection were predominantly activated to produce neutralizing antibodies against the 344 same DHF strain in the secondary infection in the absence of apparent cellular immune 345 responses. A previous report showed that DENV infection induces a high-titered 346 neutralizing antibody that can provide long-term immunity to the homologous DENV 347 serotype [22], which is consistent with our result. By contrast, the role of cellular 348 immune responses in the control of DENV infection remains to be elucidated. Our 349 results in this study may suggest that cellular immune responses and neutralizing 350 antibodies cooperatively acted to control primary DENV infection. In DENV-infected patients, it may be difficult to distinguish whether each case is primary or secondary DENV infection and also to serially collect blood samples for the immunological study in the course of the infection, which is likely the reason for the discrepancy regarding the importance of cellular immunity in DENV infection. In this point of view, our marmoset model of DENV infection will further provide important information regarding the roles of cellular immune responses in DENV infection.

357 Acknowledgements

- 358 We would like to give special thanks to members of The Corporation for Production
- and Research of Laboratory Primates for technical assistance. We also appreciate to Ms.
- 360 Tomoko Ikoma and Mizuho Fujita for technical assistance. This work was supported by
- 361 grants from the Ministry of Health, Labor and Welfare of Japan, and by the
- 362 Environment Research and Technology Development Fund (D-1007) from the Ministry
- 363 of the Environment of Japan.

364

364 Figure legends

365 Fig.1 Flow cytometric analysis of naïve, central/effector memory T cells and

366 **NK/NKT cells in marmosets.** (a) Gating strategy to indentify the CD4 and CD8 T, NK

and NKT cells. The G1 population was selected and analyzed for CD4 and CD8 T, NK

and NKT cells. (a) Profiling of naïve, central memory, and effector memory CD4 and

369 CD8 T cells in total CD4 and CD8 T cells. (b) Profiling of NK and NKT cells in total
370 lymphocytes. Results shown are representative of 3 healthy marmosets used in this
371 study.

372

373 Fig. 2 Profiling of CD4 and CD8 T, NK and NKT cells in marmosets with primary

infection of DENV-2 Mal/77/08 strain. At the primary DENV infection, two

marmosets were inoculated subcutaneously in the back with 1.9×10^5 PFU of the

376 DENV-2 Mal/77/08 strain. (a) Profiling of naïve, central memory, and effector memory

377 CD4 and CD8 T cells in total CD4 and CD8 T cells. (b) Profiling of NK and NKT cells378 in total lymphocytes. (a-b) Ci08-007.

379

Fig. 3 Frequency of CD4 and CD8 T, NK and NKT cells in marmosets with

primary infection of DENV-2 Mal/77/08 strain. At the primary DENV infection, two

marmosets were inoculated subcutaneously in the back with 1.9×10^5 PFU of the

383 DENV-2 Mal/77/08 strain. (a) Ratios of naïve, central memory, and effector memory

CD4 T cells in total CD4 T cells. (b) Ratios of naïve, central memory, and effector

385 memory CD8 T cells in total CD8 T cells. (c) Ratios of NK and NKT cells in total

- 386 lymphocytes. (a-c) Cj08-007, Cj07-011.
- 387

388 Fig. 4 Profiling of CD4 and CD8 T, NK and NKT cells in marmosets with primary

389 infection of DENV-2 DHF0663 strain. At the primary DENV infection, two

marmosets were inoculated subcutaneously in the back with 1.8×10^4 PFU of the

391 DENV-2 DHF0663 strain. (a) Profiling of naïve, central memory, and effector memory

- 392 CD4 and CD8 T cells in total CD4 and CD8 T cells. (b) Profiling of NK and NKT cells
- in total lymphocytes. (a-b) Cj07-006.
- 394

Fig. 5 Frequency of CD4 and CD8 T, NK and NKT cells in marmosets with

396 primary infection of DENV-2 DHF0663 strain. At the primary DENV infection, two

- 397 marmosets were inoculated subcutaneously in the back with 1.8×10^4 PFU of the
- 398 DENV-2 DHF0663 strain. (a) Ratios of naïve, central memory, and effector memory
- 399 CD4 T cells in total CD4 T cells. (b) Ratios of naïve, central memory, and effector
- 400 memory CD8 T cells in total CD8 T cells. (c) Ratios of NK and NKT cells in total
- 401 lymphocytes. (a-c) Cj07-006, Cj07-008.
- 402

403 Fig. 6 Profiling of CD4 and CD8 T, NK and NKT cells in marmosets with

404 re-challenging DENV-2 DHF0663 strain. In the case of the DENV re-challenge study,

405 two marmosets initially inoculated with 1.8×10^5 PFU of the DHF0663 strain were

406 re-inoculated 33 weeks after the primary challenge with 1.8×10^5 PFU of the same strain.

407 (a) Profiling of naïve, central memory, and effector memory CD4 and CD8 T cells in

- 408 total CD4 and CD8 T cells. (b) Profiling of NK and NKT cells in total lymphocytes.
- 409 (a-b) Cj07-007.
- 410

411 Fig. 7 Frequency of CD4 and CD8 T, NK and NKT cells in marmosets with

412 re-challenging DENV-2 DHF0663 strain. In the case of the DENV re-challenge study,

413 two marmosets initially inoculated with 1.8×10^5 PFU of the DHF0663 strain were

414 re-inoculated 33 weeks after the primary challenge with 1.8×10^5 PFU of the same strain.

415 (a) Ratios of naïve, central memory, and effector memory CD4 T cells in total CD4 T

416 cells. (b) Ratios of naïve, central memory, and effector memory CD8 T cells in total

417 CD8 T cells. (c) Ratios of NK and NKT cells in total lymphocytes. (a-c) Cj07-007,

418 Cj07-014.

References

420	1.	Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, Johnson S,
421		Diamond MS, Beatty PR, Harris E (2010) Lethal antibody enhancement of
422		dengue disease in mice is prevented by Fc modification. PLoS Pathog
423		6:e1000790
424	2.	Beaumier CM, Mathew A, Bashyam HS, Rothman AL (2008) Cross-reactive
425		memory CD8(+) T cells alter the immune response to heterologous secondary
426		dengue virus infections in mice in a sequence-specific manner. J Infect Dis
427		197:608-617
428	3.	Beaumier CM, Rothman AL (2009) Cross-reactive memory CD4+ T cells alter
429		the CD8+ T-cell response to heterologous secondary dengue virus infections in
430		mice in a sequence-specific manner. Viral Immunol 22:215-219
431	4.	Beaumier CM, Jaiswal S, West KY, Friberg H, Mathew A, Rothman AL (2010)
432		Differential in vivo clearance and response to secondary heterologous infections
433		by H2(b)-restricted dengue virus-specific CD8+ T cells. Viral Immunol
434		23:477-485
435	5.	Fadilah SA, Sahrir S, Raymond AA, Cheong SK, Aziz JA, Sivagengei K (1999)
436		Quantitation of T lymphocyte subsets helps to distinguish dengue hemorrhagic
437		fever from classic dengue fever during the acute febrile stage. Southeast Asian J
438		Trop Med Public Health 30:710-717
439	6.	Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ (2007) Monoclonal
440		antibody-mediated enhancement of dengue virus infection in vitro and in vivo
441		and strategies for prevention. Proc Natl Acad Sci U S A 104:9422-9427
442	7.	Green S, Pichyangkul S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Nisalak
443		A, Kurane I, Rothman AL, Ennis FA (1999) Early CD69 expression on
444		peripheral blood lymphocytes from children with dengue hemorrhagic fever. J
445		Infect Dis 180:1429-1435
446	8.	Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, Nisalak
447		A, Lew R, Innis BL, Kurane I, Rothman AL, Ennis FA (1999) Early immune
448		activation in acute dengue illness is related to development of plasma leakage
449		and disease severity. J Infect Dis 179:755-762
450	9.	Gupta S, Gollapudi S (2008) CD95-mediated apoptosis in naive, central and
451		effector memory subsets of CD4+ and CD8+ T cells in aged humans. Exp

- 453 10. Guzman MG, Alvarez M, Rodriguez-Roche R, Bernardo L, Montes T, Vazquez
 454 S, Morier L, Alvarez A, Gould EA, Kouri G, Halstead SB (2007) Neutralizing
 455 antibodies after infection with dengue 1 virus. Emerg Infect Dis 13:282-286
 456 11. Halstead SB (1979) In vivo enhancement of dengue virus infection in rhesus
- 457 monkeys by passively transferred antibody. J Infect Dis 140:527-533
- 458 12. Halstead SB (2007) Dengue. Lancet 370:1644-1652
- 459 13. Henchal EA, Henchal LS, Schlesinger JJ (1988) Synergistic interactions of
 460 anti-NS1 monoclonal antibodies protect passively immunized mice from lethal
 461 challenge with dengue 2 virus. J Gen Virol 69 (Pt 8):2101-2107
- 462 14. Hus I, Staroslawska E, Bojarska-Junak A, Dobrzynska-Rutkowska A, Surdacka
 463 A, Wdowiak P, Wasiak M, Kusz M, Twardosz A, Dmoszynska A, Rolinski J
 464 (2011) CD3+/CD16+CD56+ cell numbers in peripheral blood are correlated
 465 with higher tumor burden in patients with diffuse large B-cell lymphoma. Folia
- 466 Histochem Cytobiol 49:183-187
- 467 15. Kaufman BM, Summers PL, Dubois DR, Eckels KH (1987) Monoclonal
 468 antibodies against dengue 2 virus E-glycoprotein protect mice against lethal
 469 dengue infection. Am J Trop Med Hyg 36:427-434
- Kaufman BM, Summers PL, Dubois DR, Cohen WH, Gentry MK, Timchak RL,
 Burke DS, Eckels KH (1989) Monoclonal antibodies for dengue virus prM
 glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg
 473 41:576-580
- 474 17. Khvedelidze M, Chkhartishvili N, Abashidze L, Dzigua L, Tsertsvadze T (2008)
 475 Expansion of CD3/CD16/CD56 positive NKT cells in HIV/AIDS: the pilot
 476 study. Georgian Med News:78-83
- 477 18. Kyle JL, Balsitis SJ, Zhang L, Beatty PR, Harris E (2008) Antibodies play a
 478 greater role than immune cells in heterologous protection against secondary
 479 dengue virus infection in a mouse model. Virology 380:296-303
- 480 19. Mathew A, Rothman AL (2008) Understanding the contribution of cellular
 481 immunity to dengue disease pathogenesis. Immunol Rev 225:300-313
- 482 20. Mladinich KM, Piaskowski SM, Rudersdorf R, Eernisse CM, Weisgrau KL,
- 483 Martins MA, Furlott JR, Partidos CD, Brewoo JN, Osorio JE, Wilson NA,
- 484 Rakasz EG, Watkins DI (2012) Dengue virus-specific CD4+ and CD8+ T


485		lymphocytes target NS1, NS3 and NS5 in infected Indian rhesus macaques.
486		Immunogenetics 64:111-121
487	21.	Mueller YM, Makar V, Bojczuk PM, Witek J, Katsikis PD (2003) IL-15
488		enhances the function and inhibits CD95/Fas-induced apoptosis of human CD4+
489		and CD8+ effector-memory T cells. Int Immunol 15:49-58
490	22.	Murphy BR, Whitehead SS (2011) Immune response to dengue virus and
491		prospects for a vaccine. Annu Rev Immunol 29:587-619
492	23.	Myint KS, Endy TP, Mongkolsirichaikul D, Manomuth C, Kalayanarooj S,
493		Vaughn DW, Nisalak A, Green S, Rothman AL, Ennis FA, Libraty DH (2006)
494		Cellular immune activation in children with acute dengue virus infections is
495		modulated by apoptosis. J Infect Dis 194:600-607
496	24.	Omatsu T, Moi ML, Hirayama T, Takasaki T, Nakamura S, Tajima S, Ito M,
497		Yoshida T, Saito A, Katakai Y, Akari H, Kurane I (2011) Common marmoset
498		(Callithrix jacchus) as a primate model of dengue virus infection: development
499		of high levels of viremia and demonstration of protective immunity. J Gen Virol
500		92:2272-2280
501	25.	Omatsu T, Moi ML, Takasaki T, Nakamura S, Katakai Y, Tajima S, Ito M,
502		Yoshida T, Saito A, Akari H, Kurane I (2012) Changes in hematological and
503		serum biochemical parameters in common marmosets (Cllithrix jacchus) after
504		inoculation with dengue virus. J Med Primatol
505		doi:10.1111/j.1600-9684.2012.00552.x
506	26.	Onlamoon N, Noisakran S, Hsiao HM, Duncan A, Villinger F, Ansari AA,
507		Perng GC (2010) Dengue virus-induced hemorrhage in a nonhuman primate
508		model. Blood 115:1823-1834
509	27.	Pawitan JA (2011) Dengue virus infection: predictors for severe dengue. Acta
510		Med Indones 43:129-135
511	28.	Pitcher CJ, Hagen SI, Walker JM, Lum R, Mitchell BL, Maino VC, Axthelm
512		MK, Picker LJ (2002) Development and homeostasis of T cell memory in rhesus
513		macaque. J Immunol 168:29-43
514	29.	Rigau-Perez JG, Clark GG, Gubler DJ, Reiter P, Sanders EJ, Vorndam AV
515		(1998) Dengue and dengue haemorrhagic fever. Lancet 352:971-977
516	30.	Sabin AB (1950) The dengue group of viruses and its family relationships.
517		Bacteriol Rev 14:225-232


518	31.	Sierra B, Garcia G, Perez AB, Morier L, Rodriguez R, Alvarez M, Guzman MG
519		(2002) Long-term memory cellular immune response to dengue virus after a
520		natural primary infection. Int J Infect Dis 6:125-128
521	32.	Terabe M, Berzofsky JA (2008) The role of NKT cells in tumor immunity. Adv
522		Cancer Res 101:277-348
523	33.	Tuiskunen A, Monteil V, Plumet S, Boubis L, Wahlstrom M, Duong V, Buchy P,
524		Lundkvist A, Tolou H, Leparc-Goffart I (2011) Phenotypic and genotypic
525		characterization of dengue virus isolates differentiates dengue fever and dengue
526		hemorrhagic fever from dengue shock syndrome. Arch Virol 156:2023-2032
527	34.	Ubol S, Masrinoul P, Chaijaruwanich J, Kalayanarooj S, Charoensirisuthikul T,
528		Kasisith J (2008) Differences in global gene expression in peripheral blood
529		mononuclear cells indicate a significant role of the innate responses in
530		progression of dengue fever but not dengue hemorrhagic fever. J Infect Dis
531		197:1459-1467
532	35.	Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, Peters B,
533		Prestwood TR, Sette A, Shresta S (2009) A protective role for dengue
534		virus-specific CD8+ T cells. J Immunol 182:4865-4873
535	36.	Yauch LE, Prestwood TR, May MM, Morar MM, Zellweger RM, Peters B,
536		Sette A, Shresta S (2010) CD4+ T cells are not required for the induction of
537		dengue virus-specific CD8+ T cell or antibody responses but contribute to
538		protection after vaccination. J Immunol 185:5405-5416
539	37.	Yoshida T, Saito A, Iwasaki Y, Iijima S, Kurosawa T, Katakai Y, Yasutomi Y,
540		Reimann KA, Hayakawa T, Akari H (2010) Characterization of natural killer
541		cells in tamarins: a technical basis for studies of innate immunity. Front
542		Microbiol 1:128
543	38.	Yoshida T, Omatsu T, Saito A, Katakai Y, Iwasaki Y, Iijima S, Kurosawa T,
544		Hamano M, Nakamura S, Takasaki T, Yasutomi Y, Kurane I, Akari H (2012)
545		CD16(+) natural killer cells play a limited role against primary dengue virus
546		infection in tamarins. Arch Virol 157:363-368
547	39.	Zompi S, Santich BH, Beatty PR, Harris E (2012) Protection from secondary
548		dengue virus infection in a mouse model reveals the role of serotype
549		cross-reactive B and T cells. J Immunol 188:404-416
550		

552 **Conflict of Interest Statement:**


- 553 The authors declare that the research was conducted in the absence of any commercial
- or financial relationships that could be construed as a potential conflict of interest.


555






CD95







76

105

104

10³

0 10²

10³

0 10²


10⁵

104



10³ 104

0 10²



66


104 105


0 10²

10³


73

105





CD3



Subpopulation na	me	Subpopulation Ratios (Mean±SD: %)			
CD3+		75.7±6.4			
CD3 ⁺ CD4 ⁺		65.4±6.8			
CD3 ⁺ CD4 ⁺ CD62L ⁺ C	D95 [.] (CD4 T _N)	65.9±3.7			
CD3+CD4+CD62L+C	D95 ⁺ (CD4 Т _{см})	16.4±2.9			
CD3+CD4+CD62L-C	$D95^{\pm} (CD4 T_{EM})$	19.5±2.5			
CD3 ⁺ CD8 ⁺		29.0±8.0			
CD3+CD8+CD62L+C	D95 ⁻ (CD8 T _N)	66.7±10.2			
CD3+CD8+CD62L+C	D95 ⁺ (CD8 T _{см})	4.7±3.6			
CD3+CD8+CD62L-C	D95 [±] (CD8 T _{EM})	28.8±14.8			
CD3 ⁻ CD16 ⁺	(NK)	4.2±2.6			
CD3+CD16+	(NKT)	5.1±3.4			

 Table 1. Subpopulation ratios of lymphocytes in marmosets.

SD: Standard deviation.

Results shown are mean±SD from 3 healthy marmosets.

Subpopulation name		Subpopulation Ratios (Mean±SD: %)						
		Days after inoculation						
	_	Day 0	Day 2	Day 4	Day 7	Day 14	Day 21	
CD3 ⁺ CD4 ⁺ CD62L ⁺ CD95 ⁻	(CD4 T _N)	74.1±0.9	1.6±3.3	0.2±0.3	70.5±5.5	64.8±9.7	60.8±5.	
CD3+CD4+CD62L+CD95+	(СD4 Т _{см})	13±0.4	88.7±2.8	87.4±0.2	16.8±5.0	21.6±6.5	20±6.4	
CD3 ⁺ CD4 ⁺ CD62L ⁻ CD95 [±]	(CD4 T _{EM})	12.8±0.9	9.5±1.0	12.3±0.4	12.3±0.5	13.4±3.2	18.9±1.	
CD3+CD8+CD62L+CD95-	(CD8 T _N)	89.9±2.5	2.5±4.7	0.3±0.3	87.5±3.3	68.7±7.9	69.8±3.	
CD3+CD8+CD62L+CD95+	(СD8 Т _{см})	2.1±0.8	91.9±5.5	90.6±4.2	2.8±0.5	3.5±0.8	3.8±1.	
CD3 ⁺ CD8 ⁺ CD62L ⁻ CD95 [±]	(CD8 T _{EM})	7.8±1.6	5.6±0.8	9.0±4.1	9.5±3.1	27.6±7.2	26.3±4.	
CD3 ⁻ CD16 ⁺	(NK)	2.9±0.2	1.8±0.6	2.2±0.9	4.2±0.9	2.8±0.4	3.2±1.7	
CD3+CD16+	(NKT)	0.2±0.0	52.6±17	46.1±8.5	1.1±0.5	1.7±0.5	1.2±0.	

Table 2. Subpopulation ratios of lymphocytes in marmosets during primary DENV infection (Mal/77/08).

SD: Standard deviation.

Results shown are mean±SD from 2 marmosets as shown in Figure 3.

Subpopulation name	Subpopulation Ratios (Mean±SD: %)								
			Days after inoculation						
	_	Day 0	Day 2	Day 4	Day 7	Day 14	Day 21		
CD3 ⁺ CD4 ⁺ CD62L ⁺ CD95 ⁻	(CD4 T _N)	67.3±3.6	57.0±4.0	61.9±0.9	34.4±3.6	55.2±14	56.7±13		
CD3+CD4+CD62L+CD95+	(СD4 Т _{см})	13.9±1.3	17.5±4.1	15.2±2.5	40.0±13	33.8±10	21.3±12		
CD3+CD4+CD62L-CD95±	(CD4 T _{EM})	18.8±2.2	25.3±0.9	22.8±2.9	25.6±13	20.3±4.0	21.8±1.		
CD3 ⁺ CD8 ⁺ CD62L ⁺ CD95 ⁻	(CD8 T _N)	67.8±14	68.4±3.7	77.7±4.6	42.2±7.4	52.7±5.5	53.5±9.		
CD3 ⁺ CD8 ⁺ CD62L ⁺ CD95 ⁺	(СD8 Т _{см})	3.9±0.6	7.4±2.8	5.5±1.6	28±17	8.1±4.6	8.6±8.9		
CD3 ⁺ CD8 ⁺ CD62L ⁻ CD95 [±]	(CD8 T _{em})	28±14	23.5±6.7	16.4±6.5	28.3±18	38.2±1.9	37.0±1		
CD3-CD16+	(NK)	4.7±1.0	4.2±1.9	2.0±1.1	6.3±2.3	5.1±2.2	7.3±1.		
CD3 ⁺ CD16 ⁺	(NKT)	7.8±1.0	9.3±4.5	5.9±2.6	22.6±8.4	20.6±10	17.3±1		

 Table 3. Subpopulation ratios of lymphocytes in marmosets during primary DENV infection (DHF0663).

SD: Standard deviation.

Results shown are mean±SD from 2 marmosets as shown in Figure 5.

Supplementary Figure Legends

Supplementary Figure 1. Levels of DENV RNA in primary or re-challenge DENV-infected marmosets. Data for these graphs was extracted from the study of Omatsu T. *et al.* (2011). Marmosets were subcutaneously infected with the DENV-2 Mal/77/08 strain or with the DENV-2 DHF0663 strain. The vRNAs were detected in plasma by real-time PCR. (a) Cj08-007, Cj07-011: Mal/77/08 strain (1.9x10⁵ PFU/ml). At the primary DENV infection, two marmosets were inoculated subcutaneously in the back with 1.9 x10⁵ PFU of the DENV-2 Mal/77/08 strain. (b) Cj07-006, Cj07-008: DHF0663 strain (1.8x10⁴ PFU/ml). At the primary DENV infection, two marmosets were inoculated subcutaneously in the back with 1.8x10⁴ PFU of the DENV-2 DHF0663 strain. (c) Cj07-007, Cj07-014: DHF0663 strain (1.8x10⁵ PFU/ml). In the case of the DENV re-challenge study, two marmosets initially inoculated with 1.8x10⁵ PFU of the DHF0663 strain were re-inoculated 33 weeks after the primary challenge with 1.8x10⁵ PFU of the same virus.

Supplementary materials and methods

Animals

All animal studies were conducted in accordance with the protocols of experimental procedures that were approved by the Animal Welfare and Animal Care Committee of the National Institute of Infectious Diseases, Japan, and the National Institute of Biomedical Innovation, Japan. A total of 6 male marmosets, weighing 258-512 g, were used. DENV infection status in marmosets was used from a previous study (Supplementary Figure 1) [2]. Marmosets were caged individually at 27±2 °C in 50±10% humidity with a 12h light-dark cycle (lighting from 7:00 to 19:00) at Tsukuba

Primate Research Center, National Institute of Biomedical Innovation, Tsukuba, Japan. All animals were fed twice a day with a standard marmoset diet supplemented with fruit, eggs and milk. Water was given ad libitum. The animals were in a healthy condition and confirmed to be negative for anti-dengue virus antibodies before inoculation with dengue virus [2].

Cells

Cell culture was performed as previously described [2]. Vero cells were cultured in Minimum Essential Medium (MEM, Sigma) with 10% heat-inactivated fetal bovine serum (FBS, GIBCO) and 1% non-essential amino acid (NEAA, Sigma) at 37 °C in 5 % CO_2 . C6/36 cells were cultured in MEM with 10% FBS and 1% NEAA at 28 °C in 5 % CO_2 .

Virus

DENV strains were reported as previously described [2]. DENV type 2 (DENV-2), DHF0663 strain (Accession no. AB189122) strain was used for inoculation studies. The DENV-2, DHF0663 strain was isolated from a DHF case in Indonesia. The DENV-2, Mal/77/08 strain was isolated from imported DF cases from Maldives. The DENV-2 isolated clinical samples were propagated with C6/36 cells and were used within 4 passages on C6/36 cells. Culture supernatant from infected C6/36 cells was centrifuged at 3,000 rpm for 5 min to remove cell debris, and then stored at -80 °C until use.

Infection of marmosets with DENV

In the challenge study, the profiling of the key adaptive and innate immune cells in the

marmosets after serotype 2 of DENV (DENV-2) infection was examined. At the primary DENV infection, four marmosets were inoculated subcutaneously in the back with 1.9×10^5 plaque forming unit (PFU) of the DENV-2 Mal/77/08 strain (Cj08-007, Cj07-011) or with 1.8×10^4 PFU of the DENV-2 DHF0663 strain (Cj07-006, Cj07-008) [2]. In the case of the DENV re-challenge study, two marmosets initially inoculated with 1.8×10^5 PFU of the DHF0663 strain were re-inoculated 33 weeks after the primary challenge with 1.8×10^5 PFU of the same virus (Cj07-007, Cj07-014) [2]. Blood samples were collected on days 0, 1, 3, 7, 14, and 21 after inoculation and were used for virus titration and flow cytometric analysis. Inoculation with DENV and blood drawing was performed under anesthesia with 5 mg/kg of ketamine hydrochloride. Day 0 was defined as the day of virus inoculation. DENV viral loads in marmosets were used from a previous study (Supplementary Figure 1) [2].


Titration of viral RNA in plasma

Plasma samples were stored at -80 °C until use. Viral RNA was isolated from plasma samples, using the High Pure Viral RNA Kit (Roche Diagnostics). Levels of dengue viral RNA were determined by TaqMan real time reverse transcriptase-PCR (TaqMan RT-PCR) as previously reported [1]. One PFU/ml of the DENV-2 DHF0663 strain from plasma samples was equivalent to 285 ± 35.4 copies/ml with this method, and the detection limit was 5×10^3 copies/ml in plasma samples.

Supplementary References

 Ito M, Takasaki T, Yamada K, Nerome R, Tajima S, Kurane I (2004) Development and evaluation of fluorogenic TaqMan reverse transcriptase PCR assays for detection of dengue virus types 1 to 4. J Clin Microbiol 42:5935-5937 2. Omatsu T, Moi ML, Hirayama T, Takasaki T, Nakamura S, Tajima S, Ito M, Yoshida T, Saito A, Katakai Y, Akari H, Kurane I (2011) Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viremia and demonstration of protective immunity. J Gen Virol 92:2272-2280

Supplementary Fig. 1



Days post inoculation